Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Apr 30;4(5):443-445.
doi: 10.1016/j.jdcr.2017.12.003. eCollection 2018 Jun.

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

Sa Rang Kim  1 , Alexandra Charos  1 , William Damsky  2 , Peter Heald  2 , Michael Girardi  2 , Brett A King  2
Affiliations
Case Reports

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib

Sa Rang Kim et al. JAAD Case Rep. .
No abstract available

Keywords: ECP, extracorporeal photopheresis; EF, eosinophilic fasciitis; GDM, generalized deep morphea; HES, hypereosinophilic syndrome; IL, interleukin; JAK, Janus kinase; JAK-STAT; Janus kinase; Janus kinase inhibitor; ROM, range of motion; TGF-β, transforming growth factor beta; eosinophilic fasciitis; interleukin-4; morphea; tofacitinib; transforming growth factor-β.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A, Before treatment with tofacitinib, patient with GDM was unable to appose her hands (positive prayer sign). B, After 8 months of treatment with tofacitinib, she could fully extend her digits.
Fig 2
Fig 2
A, Before treatment with tofacitinib, pseudocellulite appearance and linear depressions (groove sign) of the right arm were prominent in patient with EF. B, After 19 months of treatment with tofacitinib and methotrexate, pseudocellulite appearance and linear depressions are resolved.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mertens J.S., Seyger M.M.B., Thurlings R.M. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol. 2017;18:491–512. - PMC - PubMed
    1. Hurabielle C., Sicre de Fontbrune F., Moins-Teisserenc H. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host-disease. Br J Dermatol. 2017 - PubMed
    1. King B., Lee A.I., Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. 2017;137:951–954. - PMC - PubMed
    1. Li S.C., Torok K.S., Pope E. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 2012;64:1175–1185. - PMC - PubMed
    1. Badea I., Taylor M., Rosenberg A., Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009;48:213–221. - PubMed

Publication types

LinkOut - more resources